Literature DB >> 2338116

Pharmacokinetics of oral cyclosporin A in diabetic children and adolescents.

C Misteli1, E Rey, G Pons, M O Richard, P d'Athis, A Legrand, P Bougneres, G Olive.   

Abstract

Cyclosporin A (CsA) pharmacokinetics was studied in 19 diabetic children (mean age: 10.6 y). They were divided into prepubertal (I) and pubertal (II) groups according to plasma oestradiol or testosterone concentrations. The kinetic study was performed after a 72 h wash out period and a single oral dose of 7.5 mg/kg CsA. CsA in blood was measured by HPLC. The kinetic parameters: Cmax, tmax, t 1/2, AUC, CL/f, Vz/f and tss were calculated. No significant difference was found between the two groups. A significant negative correlation was found between Vz and both total cholesterol (r = -0.46), VLDL + LDL - cholesterol (r = -0.49) and VLDL + LDL - phospholipids (r = -0.58). CsA kinetics at steady-state were simulated by superimposition of single dose kinetics derived from each single dose. Measured steady-state blood concentrations were correlated (r = 0.80) with the values predicted by the simulation. The results suggest that CsA adjustment dosage of the CsA may be performed after a single oral dose using blood levels measured by HPLC. This procedure requires validation in further studies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338116     DOI: 10.1007/bf00265981

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Interim report of clinical studies presented at the International Symposium on Ciclosporin in Auto-Immune Diseases, Basel, March 18-20, 1985.

Authors:  M Schmitz-Schumann
Journal:  Prog Allergy       Date:  1986

2.  Variations in pattern of pubertal changes in girls.

Authors:  W A Marshall; J M Tanner
Journal:  Arch Dis Child       Date:  1969-06       Impact factor: 3.791

Review 3.  Clinical transplantation--overview.

Authors:  T Beveridge
Journal:  Prog Allergy       Date:  1986

4.  The effect of food on cyclosporine absorption.

Authors:  R J Ptachcinski; R Venkataramanan; J T Rosenthal; G J Burckart; R J Taylor; T R Hakala
Journal:  Transplantation       Date:  1985-08       Impact factor: 4.939

5.  Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee.

Authors: 
Journal:  Circulation       Date:  1979-08       Impact factor: 29.690

6.  Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients.

Authors:  G C Yee; T P Lennon; D J Gmur; M S Kennedy; H J Deeg
Journal:  Clin Pharmacol Ther       Date:  1986-10       Impact factor: 6.875

7.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

Authors:  C R Stiller; J Dupré; M Gent; M R Jenner; P A Keown; A Laupacis; R Martell; N W Rodger; B von Graffenried; B M Wolfe
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

8.  Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus.

Authors:  R Assan; G Feutren; M Debray-Sachs; M C Quiniou-Debrie; C Laborie; G Thomas; L Chatenoud; J F Bach
Journal:  Lancet       Date:  1985-01-12       Impact factor: 79.321

9.  Improved liquid-chromatographic determination of cyclosporine, with concomitant detection of a cell-bound metabolite.

Authors:  G L Lensmeyer; B L Fields
Journal:  Clin Chem       Date:  1985-02       Impact factor: 8.327

10.  Factors associated with early remission of type I diabetes in children treated with cyclosporine.

Authors:  P F Bougneres; J C Carel; L Castano; C Boitard; J P Gardin; P Landais; J Hors; M J Mihatsch; M Paillard; J L Chaussain
Journal:  N Engl J Med       Date:  1988-03-17       Impact factor: 91.245

View more
  1 in total

Review 1.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.